Disease details

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2020-004431-24-PL (EUCTR)		28/10/2022	A Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ponesimod Versus Fingolimod During 108 Weeks of Treatment in Pediatric Participants, 10 to <18 Years Old, with Relapsing-remitting Multiple Sclerosis	Multi-center, Randomized, Double-blind, Parallel-group, Double-dummy, Active-controlled, Comparative Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ponesimod Versus Fingolimod During 108 Weeks of Treatment in Pediatric Participants, 10 to <18 Years Old, with Relapsing-remitting Multiple Sclerosis - PIONEER	Relapsing-remitting Multiple Sclerosis MedDRA version: 21.1;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Ponesimod Product Code: JNJ-67896153/ACT-128800 INN or Proposed INN: Ponesimod Other descriptive name: ACT-128800 Product Name: Ponesimod Product Code: JNJ-67896153/ACT-128800 INN or Proposed INN: Ponesimod Other descriptive name: ACT-128800 Product Name: Ponesimod Product Code: JNJ-67896153/ACT-128800 INN or Proposed INN: Ponesimod Other descriptive name: ACT-128800 Product Name: Ponesimod Product Code: JNJ-67896153/ACT-128800 INN or Proposed INN: Ponesimod Other descriptive name: ACT-128800 Product Name: Ponesimod Product Code: JNJ-67896153/ACT-128800 INN or Proposed INN:	Janssen-Cilag International NV	NULL	NA			Female: yes Male: yes	212	Phase 3	Hungary;Canada;Argentina;Brazil;Poland;Belgium;Croatia;Bulgaria;Germany;Sweden;Turkey;Austria;United Kingdom;Serbia;Portugal;United States;Estonia;Taiwan;Slovakia;Greece;Spain;Israel;Switzerland;Italy;France;Puerto Rico;Peru;Australia;Czechia;Finland
2	EUCTR2020-004431-24-DE (EUCTR)		22/09/2022	A Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ponesimod Versus Fingolimod During 108 Weeks of Treatment in Pediatric Participants, 10 to <18 Years Old, with Relapsing-remitting Multiple Sclerosis	Multi-center, Randomized, Double-blind, Parallel-group, Double-dummy, Active-controlled, Comparative Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ponesimod Versus Fingolimod During 108 Weeks of Treatment in Pediatric Participants, 10 to <18 Years Old, with Relapsing-remitting Multiple Sclerosis - PIONEER	Relapsing-remitting Multiple Sclerosis MedDRA version: 21.1;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Ponvory Product Name: Ponesimod Product Code: JNJ-67896153/ACT-128800 INN or Proposed INN: Ponesimod Other descriptive name: ACT-128800 Trade Name: Ponvory Product Name: Ponesimod Product Code: JNJ-67896153/ACT-128800 INN or Proposed INN: Ponesimod Other descriptive name: ACT-128800 Trade Name: Ponvory Product Name: Ponesimod Product Code: JNJ-67896153/ACT-128800 INN or Proposed INN: Ponesimod Other descriptive name: ACT-128800 Trade Name: Ponvory Product Name: Ponesimod Product Code: JNJ-67896153/ACT-128800 INN or Proposed INN: Ponesimod Other descriptive name: ACT-128800 Trade Name: Ponvory Product Name: Ponesimod	Janssen-Cilag International NV	NULL	NA			Female: yes Male: yes	212	Phase 3	Serbia;Portugal;United States;Estonia;Taiwan;Slovakia;Greece;Spain;Israel;Switzerland;Italy;France;Puerto Rico;Peru;Australia;Czechia;Finland;Turkey;Austria;United Kingdom;Hungary;Canada;Argentina;Brazil;Poland;Belgium;Croatia;Bulgaria;Germany;Sweden